As critical transcription factors for lymphopoiesis and lymphoid malignancies, degradation of IKZF1 and IKZF3 by the CRL4CRBN E3 ubiquitin ligase complex mediates the anti-myeloma effect of lenalidomide [57,58]. The gene discussed is IKZF3; the disease is plasma cell myeloma.